Autosomal recessive spastic paraplegia type 66 (SPG66) is a rare, inherited neurological disorder characterized by progressive muscle weakness and stiffness (spasticity) in the legs. It is caused by mutations in the SLC12A6 gene, which is responsible for the production of a protein involved in the transport of chloride ions across cell membranes. Symptoms typically begin in childhood or adolescence and worsen over time. Affected individuals may experience difficulty walking, balance problems, and muscle spasms. There is currently no cure for SPG66, but physical therapy and medications may help to manage symptoms.

The symptoms of Autosomal recessive spastic paraplegia type 66 (SPG66) vary from person to person, but may include:

- Muscle Weakness and Stiffness in the legs
- Difficulty walking, running, or climbing stairs
- Loss of balance and coordination
- Abnormal gait
- Urinary and/or fecal incontinence
- Muscle spasms
- Pain in the legs
- Fatigue
- Difficulty with fine motor skills
- Speech and language difficulties
- Cognitive impairment

Autosomal recessive spastic paraplegia type 66 (SPG66) is caused by mutations in the SLC25A24 gene. This gene provides instructions for making a protein that is involved in the transport of molecules across the inner membrane of mitochondria, which are structures within cells that convert the energy from food into a form that cells can use. Mutations in the SLC25A24 gene reduce the amount of functional protein, which disrupts the transport of molecules across the mitochondrial membrane and leads to the signs and symptoms of SPG66.

Currently, there is no known cure for Autosomal recessive spastic paraplegia type 66. Treatment focuses on managing the symptoms and preventing further complications. This may include physical therapy, occupational therapy, speech therapy, and medications to help manage muscle spasms and pain. Assistive devices such as wheelchairs, walkers, and braces may also be used to help with mobility. In some cases, surgery may be recommended to help improve mobility.

1. Having a family history of Autosomal recessive spastic paraplegia type 66.
2. Being of Ashkenazi Jewish descent.
3. Having a mutation in the SLC33A1 gene.
4. Being exposed to certain environmental factors.
5. Having a weakened immune system.

At this time, there is no known cure or medications for Autosomal recessive spastic paraplegia type 66. Treatment focuses on managing the symptoms and preventing complications. This may include physical therapy, occupational therapy, speech therapy, orthopedic devices, and medications to reduce spasticity.